These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Therapy of infantile spasms: new opportunities and emerging challenges. Mikati MA; Cornett KM Epilepsy Behav; 2010 Apr; 17(4):571-3. PubMed ID: 20097137 [No Abstract] [Full Text] [Related]
25. New drugs: pitavastatin calcium, vigabatrin, and romidepsin. Hussar DA; Christian ME J Am Pharm Assoc (2003); 2010; 50(4):548-51. PubMed ID: 20621877 [No Abstract] [Full Text] [Related]
26. Infantile spasms and vigabatrin. Visual field defects may be permanent. Lhatoo SD; Sander JW BMJ; 1999 Jan; 318(7175):57. PubMed ID: 10068225 [No Abstract] [Full Text] [Related]
28. Binasal visual field defects are not specific to vigabatrin. Gonzalez P; Sills GJ; Parks S; Kelly K; Stephen LJ; Keating D; Dutton GN; Brodie MJ Epilepsy Behav; 2009 Nov; 16(3):521-6. PubMed ID: 19815465 [TBL] [Abstract][Full Text] [Related]
30. Update of the medical treatment of West syndrome. Verrotti A; Manco R; Coppola GG; Mingione S; Chiarelli F; Iannetti P Minerva Pediatr; 2007 Jun; 59(3):249-53. PubMed ID: 17519870 [TBL] [Abstract][Full Text] [Related]
31. Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial. Darke K; Edwards SW; Hancock E; Johnson AL; Kennedy CR; Lux AL; Newton RW; O'Callaghan FJ; Verity CM; Osborne JP; Arch Dis Child; 2010 May; 95(5):382-6. PubMed ID: 20457702 [TBL] [Abstract][Full Text] [Related]
32. The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms. Silverman RB J Med Chem; 2012 Jan; 55(2):567-75. PubMed ID: 22168767 [No Abstract] [Full Text] [Related]
33. [Therapeutic options provided by new antiepileptic drugs]. Baulac M; Arzimanoglou A; Semah F; Cavalcanti D Rev Neurol (Paris); 1997 Feb; 153(1):21-33. PubMed ID: 9296153 [TBL] [Abstract][Full Text] [Related]
34. Unintended Consequences: The Story of PERF. Elterman RD; Shields WD Pediatr Neurol; 2015 Sep; 53(3):183-4. PubMed ID: 26149106 [No Abstract] [Full Text] [Related]
35. Vigabatrin pediatric dosing information for refractory complex partial seizures: results from a population dose-response analysis. Nielsen JC; Tolbert D; Patel M; Kowalski KG; Wesche DL Epilepsia; 2014 Dec; 55(12):e134-8. PubMed ID: 25311090 [TBL] [Abstract][Full Text] [Related]
36. Vigabatrin and epilepsy: further lessons in early childhood. Parisi P; Bombardieri R; Curatolo P Epilepsia; 2008 Jan; 49(1):177-8. PubMed ID: 18184225 [No Abstract] [Full Text] [Related]